These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 28425306)

  • 1. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
    Sunada S; Nakanishi A; Miki Y
    Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
    Schoonen PM; Talens F; Stok C; Gogola E; Heijink AM; Bouwman P; Foijer F; Tarsounas M; Blatter S; Jonkers J; Rottenberg S; van Vugt MATM
    Nat Commun; 2017 Jul; 8():15981. PubMed ID: 28714471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
    Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
    BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    Noordermeer SM; van Attikum H
    Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.